{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T04:56:02Z","timestamp":1770785762366,"version":"3.50.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":1981,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T00:00:00Z","timestamp":1595203200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Describe the clinical course and management of a dog that underwent hematopoietic stem cell transplantation (HSCT) for treatment of B-cell lymphoma and developed acquired circulating factor V (FV) inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Summary<\/jats:title>\n                    <jats:p>An 8-year-old male castrated Briard dog diagnosed with lymphoma (IVb, B-cell) presented for allogeneic HSCT. Despite multiple platelet, fresh frozen plasma, and red blood cell transfusions prolonged recovery and clinical bleeding occurred. Circulating acquired FV inhibitors were identified and hemorrhage subsequently was managed by immunosuppression. The dog was discharged when clinical resolution of bleeding was achieved.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>New or Unique Information Provided<\/jats:title>\n                    <jats:p>This case report describes a dog undergoing curative intent treatment for lymphoma, and subsequently acquiring factor inhibition, and was successfully managed. Specific coagulation screening to assess for coagulation factor deficiencies or inhibitors is essential in the diagnosis and treatment of patients with refractory bleeding or only transient response to blood transfusion.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.15845","type":"journal-article","created":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T04:28:35Z","timestamp":1595219315000},"page":"2096-2100","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Acquired factor V inhibitors after allogeneic hematopoietic stem cell transplantation in a dog"],"prefix":"10.1093","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5874-7762","authenticated-orcid":false,"given":"Joseph","family":"Masciana","sequence":"first","affiliation":[{"name":"VCA West Los Angeles - Emergency and Critical Care , Los Angeles, California,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Peterson","sequence":"additional","affiliation":[{"name":"VCA West Los Angeles - Emergency and Critical Care , Los Angeles, California,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Chretin","sequence":"additional","affiliation":[{"name":"VCA West Los Angeles \u2013 Oncology , Los Angeles, California,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,9,1]]},"reference":[{"issue":"5","key":"2026020922075185400_jvim15845-bib-0001","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1476-4431.2009.00437.x","article-title":"Factor VIII inhibitors complicating treatment of postoperative bleeding in a dog with hemophilia a","volume":"19","author":"O'Kelley","year":"2009","journal-title":"J Vet Emerg Crit Care"},{"issue":"5","key":"2026020922075185400_jvim15845-bib-0002","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0950-3536(98)80050-4","article-title":"Acquired factor V inhibitors","volume":"11","author":"Kn\u00f6bl","year":"1998","journal-title":"Baillieres Clin Haematol"},{"issue":"5","key":"2026020922075185400_jvim15845-bib-0003","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.5858\/arpa.2016-0445-RS","article-title":"Factor V inhibitors: a diagnostic and therapeutic challenge","volume":"141","author":"Olson","year":"2017","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"2026020922075185400_jvim15845-bib-0004","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11239-010-0529-6","article-title":"Acquired factor V inhibitors: a systematic review","volume":"31","author":"Franchini","year":"2011","journal-title":"J Thromb Thrombolysis"},{"issue":"5","key":"2026020922075185400_jvim15845-bib-0005","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1111\/jth.13114","article-title":"Acquired factor V inhibitor after exposure to topical human thrombin related to an otorhinolaryngological procedure","volume":"13","author":"Donohoe","year":"2015","journal-title":"J Thromb Haemost"},{"key":"2026020922075185400_jvim15845-bib-0006","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.thromres.2017.06.007","article-title":"Iatrogenic acquired factor V inhibitors: a case report and review of the French pharmacovigilance database","volume":"157","author":"Theron","year":"2017","journal-title":"Thromb Res"},{"issue":"5","key":"2026020922075185400_jvim15845-bib-0007","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1160\/TH07-03-0171","article-title":"Acquired factor V inhibitor after haematopoietic stem cell transplantation","volume":"98","author":"Milojkovic","year":"2007","journal-title":"Thromb Haemost"},{"key":"2026020922075185400_jvim15845-bib-0008","doi-asserted-by":"crossref","first-page":"994","DOI":"10.2460\/javma.246.9.994","article-title":"Allogeneic hematopoietic cell transplantation in a dog with acute large granular lymphocytic leukemia","volume":"246","author":"Suter","year":"2015","journal-title":"J Am Vet Med Assoc"},{"issue":"5","key":"2026020922075185400_jvim15845-bib-0009","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0022-2143(99)90062-8","article-title":"Clinical and laboratory manifestations of anti-factor V antibodies","volume":"133","author":"Ortel","year":"1999","journal-title":"J Lab Clin Med"},{"issue":"5","key":"2026020922075185400_jvim15845-bib-0010","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1177\/1076029606293438","article-title":"Spectrum of bleeding in acquired factor V inhibitor: a summary of 33 cases","volume":"12","author":"Wiwanitkit","year":"2006","journal-title":"Clin Appl Thromb Hemost"},{"issue":"5","key":"2026020922075185400_jvim15845-bib-0011","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/j.1365-2044.2009.05945.x","article-title":"Acquired factor V inhibitor in a critically ill patient","volume":"64","author":"Morris","year":"2009","journal-title":"Anaesthesia"},{"key":"2026020922075185400_jvim15845-bib-0012","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.thromres.2018.09.052","article-title":"Acquired factor V inhibitor-related severe bleeding due to unformed prothrombinase complex","volume":"171","author":"Mitsuhashi","year":"2018","journal-title":"Thromb Res"},{"issue":"5","key":"2026020922075185400_jvim15845-bib-0013","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/MAJ.0b013e31820375be","article-title":"Postoperative bleeding in an elderly patient from acquired factor V inhibitor: rapid response to immunosuppressive therapy","volume":"341","author":"Bobba","year":"2011","journal-title":"Am J Med Sci"},{"issue":"5","key":"2026020922075185400_jvim15845-bib-0014","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/ajh.10172","article-title":"High-titer acquired factor V inhibitor responsive to corticosteroids and cyclophosphamide in a patient with two malignant tumors","volume":"71","author":"Bayani","year":"2002","journal-title":"Am J Hematol"},{"key":"2026020922075185400_jvim15845-bib-0015","first-page":"S427","article-title":"Clotting factor deficiency in early trauma-associated coagulopathy","volume":"71","author":"Rizoli","year":"2011","journal-title":"J Trauma: Inj Infect Critic Care"},{"key":"2026020922075185400_jvim15845-bib-0016","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s12185-018-2561-9","article-title":"A high titer of acquired factor V inhibitor in a hemodialysis patient who developed arterial thrombosis","volume":"109","author":"Ogawa","year":"2019","journal-title":"Int J Hematol"},{"issue":"5","key":"2026020922075185400_jvim15845-bib-0017","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.2169\/internalmedicine.55.6459","article-title":"Acquired factor V inhibitor","volume":"55","author":"Hirai","year":"2016","journal-title":"Intern Med"},{"issue":"5","key":"2026020922075185400_jvim15845-bib-0018","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/ajh.21056","article-title":"Successful treatment with rituximab in a patient with an acquired factor V inhibitor","volume":"83","author":"Lebrun","year":"2008","journal-title":"Am J Hematol"},{"issue":"5","key":"2026020922075185400_jvim15845-bib-0019","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.V39.6.751.751","article-title":"Nature of the defect in congenital factor V deficiency: study in a patient with an acquired circulating anticoagulant","volume":"39","author":"Fratantoni","year":"1972","journal-title":"Blood"},{"issue":"5","key":"2026020922075185400_jvim15845-bib-0020","first-page":"303","article-title":"Inhibitor to factor V in severe factor V congenital deficiency. A case report","volume":"27","author":"Mazzucconi","year":"1985","journal-title":"Nouv Rev Fr Hematol"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvim.15845","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvim.15845","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvim.15845","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/34\/5\/2096\/66661095\/jvim15845.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/34\/5\/2096\/66661095\/jvim15845.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T03:13:57Z","timestamp":1770693237000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/34\/5\/2096\/8448370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.15845","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9]]},"published":{"date-parts":[[2020,9,1]]},"assertion":[{"value":"2020-03-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}